Proton pump inhibitors (ppis) are used in the management of dyspepsia, gastro-oesophageal reflux and peptic ulceration of the five ppis licensed for use in the united kingdom (omeprazole, lansoprazole, esomeprazole, pantoprazole and rabeprazole) only omeprazole, for which there is the most documented data on pregnancy outcome following exposure, is licensed for use in pregnancy. Omeprazole pregnancy uptodate. Drugscom provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products this material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment data sources include ibm watson micromedex (updated 10 aug 2020), cerner multum™ (updated 3 aug 2020), wolters kluwer™ (updated.
omeprazole pregnancy uptodate
Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation can j gastroenterol 12(3):225-7 matok i, et al 2012 the safety of fetal exposure to proton-pump inhibitors during pregnancy dig dis sci 57(3):699-705 pasternak b, hviid a 2010 use of proton pump inhibitors in early pregnancy and the risk of birth. Pregnancy. there are no adequate and well-controlled studies in pregnant women; available epidemiologic data fail to demonstrate an increased risk of major congenital malformations or other adverse pregnancy outcomes with first trimester omeprazole use; reproduction studies in rats and rabbits resulted in dose-dependent embryo-lethality at omeprazole doses that were approximately 3.4 to 34. In rabbits, omeprazole in a dose range of 6.9 to 69.1 mg/kg/day (about 3.4 to 34 times an oral human dose of 40 mg on a body surface area basis) administered during organogenesis produced dose-related increases in embryo-lethality, fetal resorptions, and pregnancy disruptions..
0 comments:
Post a Comment